ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to find out whether treatment with valganciclovir is safe and effective in preventing CMV organ damage in persons with HIV infection at risk for CMV disease. Eligible subjects will be CMV seropositive, currently receiving no CMV prophylaxis, with no evidence of CMV end organ disease, have a CD4 cell count <100 cells/ mm3, and a plasma HIV RNA >400 copies/mL. Subjects must either have, at time of screening, been receiving antiretroviral therapy continuously for >3 months or not be receiving antiretroviral therapy and not planning to initiate antiretroviral therapy for at least 3 months after entering the study.